CME Group (CME) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
3 Feb, 2026Executive summary
Achieved record Q2 2024 revenue of $1.53 billion, up 13% year-over-year, with record adjusted net income of $932 million and net income of $883 million; diluted EPS reached $2.42, and adjusted EPS $2.56.
Average daily volume (ADV) reached 25.9 million contracts, up 14% year-over-year, with broad-based growth across all asset classes and record non-U.S. ADV of 7.8 million contracts.
Volume and open interest grew in every asset class for the first time in over a decade.
Continued focus on capital efficiencies, innovation, and client needs, including a Google Cloud partnership for trading infrastructure.
Operating margin improved to 69.1% adjusted and 65.3% GAAP, driven by higher volumes and increased market volatility.
Financial highlights
Q2 2024 revenue: $1.53 billion, up from $1.36 billion in Q2 2023; total H1 2024 revenue: $3.02 billion.
Net income for Q2: $883 million; adjusted net income: $932 million; H1 net income: $1.74 billion.
Market data revenue increased 7% to $175 million; other revenue rose over 35% to $107 million.
Adjusted expenses were $474 million; capital expenditures for Q2 were $17 million.
Cash and equivalents at period end: $2.0 billion; total debt: $3.4 billion as of June 30, 2024.
Outlook and guidance
Tracking well against full-year guidance: 1.5%-2% increase in clearing/transaction fees, 3%-5% in data products, and 2.5%-3% total revenue impact from pricing changes.
Expense guidance unchanged; expect ~$60 million increase in H2 due to marketing, technology/cloud migration, and compensation.
Focus remains on capital efficiencies, new product launches, and value creation through Google Cloud partnership.
Management expects to maintain investment grade credit ratings and strong liquidity, with no material changes in market risk exposure since year-end 2023.
No immediate financial impact from the new colocation facility; future guidance will reflect any changes.
Latest events from CME Group
- Shareholders will vote on director elections, auditor ratification, and key governance amendments.CME
Proxy filing23 Mar 2026 - Shareholders to vote on major governance reforms, executive pay, and director elections.CME
Proxy filing23 Mar 2026 - Proposal to eliminate Class B director election rights, with payments to affected shareholders.CME
Proxy Filing12 Mar 2026 - Shareholders to vote on eliminating Class B director election rights amid record financial performance.CME
Proxy Filing12 Mar 2026 - Global growth, product innovation, and high margins drive record performance and shareholder returns.CME
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Record 2025 growth fueled by innovation, global reach, and strong capital efficiencies.CME
Investor presentation3 Mar 2026 - Record revenue, earnings, and trading volumes in 2025, with strong capital returns.CME
Q4 20254 Feb 2026 - Record financials, all proposals approved, and strong outlook amid competition and litigation.CME
AGM 20253 Feb 2026 - Strong volumes and global uncertainty drive growth focus in equities and credit, with regulatory vigilance.CME
Piper Sandler Global Exchange and Trading Conference 20241 Feb 2026